{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:45:08Z","timestamp":1771541108212,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.hrtlng.2013.05.004","type":"journal-article","created":{"date-parts":[[2013,7,6]],"date-time":"2013-07-06T00:16:02Z","timestamp":1373069762000},"page":"262-266","source":"Crossref","is-referenced-by-count":15,"title":["Amiodarone-induced pulmonary toxicity: Case study with syndrome analysis"],"prefix":"10.1016","volume":"42","author":[{"given":"Theodore E.","family":"Van Cott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen S.","family":"Yehle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan K.","family":"DeCrane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet R.","family":"Thorlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrtlng.2013.05.004_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/187152910790780032","article-title":"Amiodarone \u2013 a \u2018broad spectrum\u2019 antiarrhythmic drug","volume":"10","author":"Punnam","year":"2010","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2125.2008.03177.x","article-title":"Amiodarone-induced pulmonary toxicity","volume":"66","author":"Ernawati","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/01.CIR.82.1.51","article-title":"Clinical features of amiodarone-induced pulmonary toxicity","volume":"82","author":"Dusman","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s001340050627","article-title":"Acute amiodarone-induced lung toxicity","volume":"24","author":"Donaldson","year":"1998","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib5","series-title":"AHFS: Drug Information","year":"2013"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib6","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1161\/01.CIR.72.5.1064","article-title":"Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy","volume":"72","author":"Adams","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/019262339702500111","article-title":"Cationic amphiphilic drug-induced phospholipidosis","volume":"25","author":"Halliwell","year":"1997","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1092-9134(97)80008-1","article-title":"Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry","volume":"1","author":"Bedrossian","year":"1997","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11532320-000000000-00000","article-title":"Amiodarone: review of pulmonary effects and toxicity","volume":"33","author":"Papiris","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archinte.1987.00370010054014","article-title":"Amiodarone pulmonary toxicity. Clinical, radiologic, and pathologic correlations","volume":"147","author":"Kennedy","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib11","doi-asserted-by":"crossref","first-page":"L1189","DOI":"10.1152\/ajplung.2001.281.5.L1189","article-title":"Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes","volume":"281","author":"Baritussio","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijcard.2008.02.027","article-title":"Relationship between amiodarone-induced subclinical lung toxicity and Th1\/Th2 balance","volume":"134","author":"Kuruma","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/00984109708984070","article-title":"Amiodarone-induced pulmonary toxicity in Fischer rats: release of tumor necrosis factor alpha and transforming growth factor beta by pulmonary alveolar macrophages","volume":"52","author":"Reinhart","year":"1997","journal-title":"J\u00a0Toxicol Environ Health"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib14","doi-asserted-by":"crossref","first-page":"L1039","DOI":"10.1152\/ajplung.2000.278.5.L1039","article-title":"Amiodarone induces apoptosis of human and rat alveolar epithelial cells in\u00a0vitro","volume":"278","author":"Bargout","year":"2000","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1034\/j.1600-0773.2003.920204.x","article-title":"Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists","volume":"92","author":"Uhal","year":"2003","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1742-7843.2007.00006.x","article-title":"Amiodarone induces angiotensinogen gene expression in lung alveolar epithelial cells through activation protein-1","volume":"100","author":"Uhal","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3181\/00379727-212-44019","article-title":"An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity","volume":"212","author":"Reasor","year":"1996","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib18","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1111\/j.1540-8159.1993.tb02330.x","article-title":"Can amiodarone pulmonary toxicity be predicted in patients undergoing implantable cardioverter defibrillator implantation?","volume":"16","author":"Hawthorne","year":"1993","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib19","first-page":"III407","article-title":"Amiodarone-related postoperative adult respiratory distress syndrome","volume":"84","author":"Greenspon","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib20","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1378\/chest.105.6.1642","article-title":"Amiodarone and the development of ARDS after lung surgery","volume":"105","author":"Van Mieghem","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/0002-9149(88)90991-5","article-title":"Fatal postoperative amiodarone pulmonary toxicity","volume":"62","author":"Kay","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1742-1241.2010.02426.x","article-title":"Rhythm control agents and adverse events in patients with atrial fibrillation","volume":"64","author":"Taylor","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib23","first-page":"413","article-title":"Antiarrhythmic drug-induced side effects: a prospective survey of 300 patients","volume":"50","author":"Vigreux","year":"1995","journal-title":"Therapie"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00045391-200607000-00007","article-title":"Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone","volume":"13","author":"Bongard","year":"2006","journal-title":"Am J Ther"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.amjcard.2004.09.044","article-title":"Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study","volume":"95","author":"Olshansky","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/0735-1097(88)90321-X","article-title":"Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests","volume":"12","author":"Magro","year":"1988","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1540-8167.2010.01764.x","article-title":"A\u00a0short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study","volume":"21","author":"Le Heuzey","year":"2010","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0735-1097(97)00220-9","article-title":"Adverse effects of low dose amiodarone: a meta-analysis","volume":"30","author":"Vorperian","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.amjcard.2011.04.024","article-title":"Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone","volume":"108","author":"Jackevicius","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib30","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1253\/circj.71.1610","article-title":"Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone","volume":"71","author":"Yamada","year":"2007","journal-title":"Circ J"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib31","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1378\/chest.123.2.646","article-title":"Pulmonary toxicity in patients receiving low-dose amiodarone","volume":"123","author":"Ott","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0272-5231(03)00144-8","article-title":"Amiodarone pulmonary toxicity","volume":"25","author":"Camus","year":"2004","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib33","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.hrthm.2007.07.020","article-title":"A\u00a0practical guide for clinicians who treat patients with amiodarone: 2007","volume":"4","author":"Goldschlager","year":"2007","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib34","first-page":"e269","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib35","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.jacc.2006.07.010","volume":"48","author":"Zipes","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.hrtlng.2013.05.004_bib36","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.02.032","volume":"51","author":"Epstein","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00007611-199601000-00016","article-title":"Recurrent amiodarone pulmonary toxicity","volume":"89","author":"Chendrasekhar","year":"1996","journal-title":"South Med J"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.7326\/0003-4819-97-6-839","article-title":"Amiodarone pulmonary toxicity","volume":"97","author":"Marchlinski","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib39","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1378\/chest.86.4.541","article-title":"Prospective evaluation of amiodarone pulmonary toxicity","volume":"86","author":"Kudenchuk","year":"1984","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib40","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/BF00542206","article-title":"Amiodarone and pulmonary fibrosis","volume":"24","author":"Morera","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib41","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0002-9149(02)02213-0","article-title":"Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone","volume":"89","author":"Kharabsheh","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1445-5994.2006.01068.x","article-title":"Monitoring the use of amiodarone: compliance with guidelines","volume":"36","author":"Burgess","year":"2006","journal-title":"Intern Med J"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib43","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.clinthera.2009.06.014","article-title":"Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review","volume":"31","author":"Snider","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib44","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1111\/j.1540-8167.2006.00583.x","article-title":"Dronedarone: an emerging agent with\u00a0rhythm- and rate-controlling effects","volume":"17","author":"Wegener","year":"2006","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib45","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMoa1109867","article-title":"Dronedarone in high-risk permanent atrial fibrillation","volume":"365","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hrtlng.2013.05.004_bib46","unstructured":"U.S. Food and Drug Administration. 2011. FDA Drug Safety Communication: Review Update of Multaq (Dronedarone) and Increased Risk of Death and Serious Cardiovascular Adverse Events. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm283933.htm."}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956313001416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956313001416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T08:34:54Z","timestamp":1539678894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956313001416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0147956313001416"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2013.05.004","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}